1258 Upsala Rd
Sanford, FL 32771
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2024 All rights reserved
AANEPI05243a
Disclaimer
is resource is for informational purposes only, intended as a quick-reference tool based on the cited
source guideline(s), and should not be used as a substitute for the independent professional judgment
of healthcare providers. Practice guidelines are unable to account for every individual variation
among patients or take the place of clinician judgment, and the ultimate decision concerning the
propriety of any course of conduct must be made by healthcare providers aer consideration of
each individual patient situation. Guideline Central does not endorse any specific guideline(s) or
guideline recommendations and has not independently verified the accuracy hereof. Any use of this
resource or any other Guideline Central resources is strictly voluntary.
Abbreviations
ASD, autism spectrum disorder; ASMs, antiseizure medications; IQ, intelligence quotient;
MCMs, major congenital malformations; NTD, neural tube defect; PWECP, people with
epilepsy of childbearing potential; SGA, small for gestational age
Source
Pack AM, Oskoui M, Williams Roberson S, et al. Teratogenesis, perinatal, and
neurodevelopmental outcomes aer in utero exposure to antiseizure medication:
Practice guideline from the AAN, AES, and SMFM. Neurolog y. 2024;102(11). doi:10.1212/
WNL.0000000000209279
